Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on the publication date for the draft commissioning policy for Chemosaturation therapy.

The Department and the National Health Service in England are committed to ensuring that cancer patients have timely access to treatment and tailored medical support. In 2016, NHS England concluded that there was insufficient evidence to make chemosaturation treatment available to patients on the NHS. NHS England is currently in the early stages of policy development for chemosaturation to treat metastatic uveal melanoma where surgery to remove or destroy affected cells and tissue in the liver is not feasible.

National Institute for Health and Care Excellence (NICE) guidance recommends that chemosaturation can be used for patients with secondary liver metastases resulting from a primary ocular melanoma, provided special arrangements are in place. A special arrangements recommendation states that clinicians using the procedure should inform the clinical governance lead in their trust, tell the patient about the uncertainties regarding the safety and efficacy of the procedure, and collect further data by means of audit or research. NICE is in the process of updating its guidance, with final guidance expected on 15 October 2026. The first committee meeting, to discuss the evidence, is expected to take place on 16 April 2026. Further information is available at the following link:

https://www.nice.org.uk/guidance/indevelopment/gid-ipg10448